Quest Diagnostics (DGX) Tops Q4 EPS by 6c, Beats on Revenue; Offers FY26 Guidance

Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $2.42, $0.06 better than the analyst estimate of $2.36. Revenue for the quarter came in at $2.81 billion versus the consensus estimate of $2.75 billion.

GUIDANCE:

Quest Diagnostics sees FY2026 EPS of $10.50-$10.70, versus the consensus of $10.42. Quest Diagnostics sees FY2026 revenue of $11.7-11.82 billion, versus the consensus of $11.36 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
• RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)